BION 1301

Drug Profile

BION 1301

Alternative Names: BION-1301

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 15 Nov 2017 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03340883)
  • 31 Oct 2017 US FDA approves IND application for BION 1301 in Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top